Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab mafodotin + lenalidomide + dexamethasone in transplant-ineligible newly diagnosed multiple myeloma
2024-517723-39-00Phase 2Authorised
- Sponsor
- Hellenic Society of Hematology
- Start
- Nov 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belantamab mafodotin in multiple myeloma (MM), sponsored by Hellenic Society of Hematology. Primary endpoints: Number of participants with dose-limiting toxicities (DLTs), Number of participants with adverse events (AEs) and serious adverse events (SAEs) and 1 more. Planned start Nov 2024; status: authorised.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-517723-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517723-39-00.